Skip to Primary Navigation

Skip to main content

FDA targets companies marketing unapproved weight‑loss drugs online

Photo of Food and Drug Administration (FDA) Commissioner Marty Makary speaking during an event where President Donald Trump made an announcement on lowering drug prices in the Oval Office at the White House
FDA Commissioner Marty Makary. Photo: Andrew Harnik/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The FDA’s latest round of warning letters points to an intensifying regulatory trend targeting companies marketing and selling GLP-1 and related compounds online.

The US Food and Drug Administration (FDA) has issued a new raft of warning letters to firms marketing glucagon‑like peptide‑1 (GLP‑1) receptor agonists and related compounds without required regulatory authorization.

On April 7, 2026, the FDA cited seven companies for distributing GLP‑1 products, dual GLP‑1/glucose‑dependent insulinotropic polypeptide (GIP) products,

Register for free to keep reading

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free
Sign in
, , , , ,